Hypoxia-inducible factor 1-alpha–von Hippel-Lindau protein interface (HIF-1α–pVHL interface)

The Hypoxia-inducible factor 1-alpha–von Hippel-Lindau protein (HIF-1α–pVHL) interface is a critical regulatory node in the cellular response to oxygen levels. Under normoxic conditions, the oxygen-dependent degradation domain (ODDD) of HIF-1α is hydroxylated at specific proline residues (Pro402 and Pro564) by prolyl hydroxylase domain (PHD) enzymes, creating a high-affinity binding site for the pVHL E3 ubiquitin ligase complex (UniProt Q16665, P40337). This interaction leads to the polyubiquitination and rapid proteasomal degradation of HIF-1α, maintaining low basal levels of the transcription factor. In hypoxia, or through pharmacological inhibition of this interface, HIF-1α is stabilized, translocates to the nucleus, and dimerizes with HIF-1β to activate the transcription of genes involved in erythropoiesis, angiogenesis, and glycolysis (Galdeano et al., J Med Chem, 2014; PMID: 24900154). This interface is a major therapeutic target; small molecule inhibitors like VH298 are being explored to stabilize HIF-1α for treating anemia and ischemic injuries. Furthermore, the pVHL-binding pocket is a cornerstone of Proteolysis Targeting Chimera (PROTAC) technology, where VHL ligands are used as 'warheads' to recruit the E3 ligase machinery to non-native target proteins for induced degradation.

Other names

HIF-1α oxygen-dependent degradation domainHIF-1α ODD domainVHL-HIF-1α interaction siteHIF-1α–pVHL complexpVHL:HIF-1α-OH interface

Small molecule inhibitors (VHL ligands) bind to the hydroxyproline-binding pocket of the von Hippel-Lindau protein (pVHL), competitively blocking the recruitment of hydroxylated HIF-1α. This prevents the polyubiquitination and subsequent proteasomal degradation of HIF-1α, leading to its stabilization and the activation of the hypoxic transcriptional program (Frost et al., Nat Commun, 2016; PMID: 27708256).